A New PsA Drug Brings Relief, But Getting an Rx Is a Challenge
July 29, 2025
Doctors, patients struggle with new drug coverage. The recent approval of a new drug to treat psoriatic arthritis (PsA) was
Doctors, patients struggle with new drug coverage. The recent approval of a new drug to treat psoriatic arthritis (PsA) was
Rheumatologists expect new mechanisms of action to reshape the SLE landscape as demand grows for safer, more effective options—particularly therapies
Despite new market entrants in the form of Gilead’s Livdelzi and Ipsen’s Iqirvo, US gastroenterologists report nearly half of PBC
Research reveals differences in prescribing patterns, treatment goals, and enthusiasm for emerging therapies including Novartis’ Fabhalta and NovelMed’s ruxoprubart, as
The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of
More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next
New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including
Systemic sclerosis and myositis interstitial lung disease subtypes flagged as most difficult to manage; specialists cite lack of effective treatments
New data released from Spherix Global Insights highlights exciting opportunities in both EU and US for launch brands Hympavzi (Pfizer),
Findings from Spherix’s fourth annual patient chart audit of more than 500 FSGS patients reveal not only a large unmet
Spherix Global Insights’ new patient audit on transfusion-dependent thalassemia reveals strong physician interest in emerging treatments like mitapivat and etavopivat,
Despite early access friction, Bimzelx’s clinical promise and prescriber satisfaction suggest long-term opportunity in PsA and axSpA. Exton, PA., June
